Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16200215 | 0.79 | GRM4 (0.46) | KDM4EPIN1GRM4LMNACYP1A2 | |
| SCHEMBL1705163 | 0.77 | KDM4E (0.46) | KDM4EPIN1NOS3NOS1NOS2 | |
| SCHEMBL409030 | 0.72 | KDM4E (0.55) | KDM4EPIN1NOS3NOS1NOS2 | |
| SCHEMBL7874577 | 0.71 | KDM4E (0.56) | KDM4EPIN1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL9650595 | 0.70 | GRM4 (0.39) | KDM4EPIN1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL28670387 | 0.70 | KDM4E (0.53) | KDM4EPIN1NOS3NOS1NOS2 | |
| Phosphine SCHEMBL17979775 | 0.70 | KDM4E (0.53) | KDM4EPIN1NOS3NOS1NOS2 | |
| Ethylene SCHEMBL27741856 | 0.68 | KDM4E (0.52) | KDM4EPIN1NOS3NOS1NOS2 | |
| SCHEMBL4379584 | 0.67 | MEN1 (0.62) | KDM4EPOLBMAP4K4LTA4HPTGS2 | |
| SCHEMBL1817017 | 0.67 | KDM4E (0.43) | KDM4EPIN1GRM4LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112812105-B | Aminopyridyloxy pyrazole derivative, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-112812105-A | Aminopyridyloxypyrazole derivative and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-05-18 | — | — | CN | claimed |
| CN-112812105-B | Aminopyridyloxy pyrazole derivative, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-112812105-B | Aminopyridyloxy pyrazole derivative, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-112812105-B | Aminopyridyloxy pyrazole derivative, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| EP-3836929-A1 | METHODS OF TREATING LIVER DISEASES | Camp4 Therapeutics Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112812105-A | Aminopyridyloxypyrazole derivative and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112812105-A | Aminopyridyloxypyrazole derivative and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112812105-A | Aminopyridyloxypyrazole derivative and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-20200208128-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2020-07-02 | — | — | US | disclosed |
| EP-3204377-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | Eli Lilly and Company (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-3204377-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | Eli Lilly and Company (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2016057278-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057278-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200208128-A1 | METHODS OF TREATING LIVER DISEASES | LIPC, PNPLA2, PNLIP | KDM4E 2781/4885PIN1 3751/4885NOS3 153/4885 |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | KDM4E 2911/4885PIN1 4020/4885NOS3 539/4885 |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | TGFBR1, TGFBR2, PDGFRB | KDM4E 2430/4885PIN1 3928/4885NOS3 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.